IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results …

E Keystone, HP Tony, A Cantagrel… - Annals of the …, 2008 - ard.bmj.com
Objectives: The phase III RADIATE study examined the efficacy and safety of tocilizumab, an
anti-IL-6 receptor monoclonal antibody in patients with rheumatoid arthritis (RA) refractory to …
被引用次数：1430 相关文章
[PDF] cyberleninka.org

[PDF][PDF] IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals …

P Emery, E Keystone, HP Tony, A Cantagrel… - Ann Rheum …, 2008 - cyberleninka.org
ABSTRACT Objectives: The phase III RADIATE study examined the efficacy and safety of
tocilizumab, an anti-IL-6 receptor monoclonal antibody in patients with rheumatoid arthritis …
[PDF] scienceopen.com

[PDF][PDF] IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals …

P Emery, E Keystone, HP Tony, A Cantagrel… - Ann Rheum …, 2008 - scienceopen.com
ABSTRACT Objectives: The phase III RADIATE study examined the efficacy and safety of
tocilizumab, an anti-IL-6 receptor monoclonal antibody in patients with rheumatoid arthritis …

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results …

P Emery, E Keystone, HP Tony, A Cantagrel… - 2008 - pubmed.ncbi.nlm.nih.gov
Objectives The phase III RADIATE study examined the efficacy and safety of tocilizumab, an
anti-IL-6 receptor monoclonal antibody in patients with rheumatoid arthritis (RA) refractory to …

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results …

P Emery, E Keystone, HP Tony… - Annals of the …, 2008 - researchinformation.amsterdamumc …
Objectives: The phase III RADIATE study examined the efficacy and safety of tocilizumab, an
anti-IL-6 receptor monoclonal antibody in patients with rheumatoid arthritis (RA) refractory to …

[引用][C] IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals …

P EMERY - Ann Rheum Dis., 2008 - cir.nii.ac.jp
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with
rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals : results from a 24-week …

[引用][C] IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals …

P EMERY, E KEYSTONE, HP TONY… - Annals of the …, 2008 - pascal-francis.inist.fr
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with
rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals : results from a 24-week …

IL-6 Receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics: results from a 24-week …

P Emery, E Keystone, HP Tony, A Cantagrel… - Annals of the …, 2008 - ard.bmj.com
Objectives: The Phase III RADIATE study examined efficacy and safety of tocilizumab, an
anti-interleukin-6 receptor monoclonal antibody in patients with rheumatoid arthritis (RA) …
[PDF] researchgate.net

[PDF][PDF] IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals …

P Emery, E Keystone, HP Tony, A Cantagrel… - Ann Rheum …, 2008 - researchgate.net
ABSTRACT Objectives: The phase III RADIATE study examined the efficacy and safety of
tocilizumab, an anti-IL-6 receptor monoclonal antibody in patients with rheumatoid arthritis …
[PDF] psu.edu

[PDF][PDF] IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals …

P Emery, E Keystone, HP Tony, A Cantagrel… - Ann Rheum Dis, 2008 - Citeseer
ABSTRACT Objectives: The phase III RADIATE study examined the efficacy and safety of
tocilizumab, an anti-IL-6 receptor monoclonal antibody in patients with rheumatoid arthritis …